It is in Laval, at the National Institute for Scientific Research (INRS), that Moderna will set up its RNA-based vaccine production plant. After a suspense of several months, the pharmaceutical giant announced in April that it was choosing the Montreal region rather than Toronto, but the exact location had not yet been determined.
Posted at 10:12 a.m.
A year after announcing that it would set up a factory in Canada, the American biopharmaceutical company, Moderna announces Thursday that it has signed a purchase contract with the National Institute for Scientific Research (INRS) for land in the park of biotechnology from Laval.
“We are pleased to have found the ideal location for the planned construction of our mRNA vaccine manufacturing facility,” Moderna said in a statement.
Construction of the biofabrication plant is expected to begin in 2022, Moderna says, and the plant is expected to be operational by the end of 2024, subject to planning and regulatory approvals.
“This site offers enormous synergy opportunities for Moderna thanks to its proximity to a renowned research institution and corresponds to the requirements of the project and its importance for all Quebecers and Canadians. »
Moderna looks forward to working with the City of Laval in the early implementation of this project and will share more information once the due diligence is complete.
Moderna is one of two major makers of messenger RNA COVID-19 vaccines in the world – the other being Pfizer/BioNTech.